BCYC241220C15000
- 6.40
- 0.000.00%
Bicycle Therapeutics Newsroom
Needham Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $38
Bicycle Therapeutics Analyst Ratings
Stephens Initiates Bicycle Therapeutics(BCYC.US) With Hold Rating, Announces Target Price $25
Morgan Stanley Initiates Bicycle Therapeutics(BCYC.US) With Hold Rating, Announces Target Price $30
JMP Securities Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $32
Barclays Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $55
RBC Capital Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $35
RBC Capital Reiterates Outperform on Bicycle Therapeutics, Maintains $35 Price Target
A Quick Look at Today's Ratings for Bicycle Therapeutics(BCYC.US), With a Forecast Between $32 to $55
Bicycle Therapeutics Analyst Ratings
Leerink Partners Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Announces Target Price $30
A Quick Look at Today's Ratings for Bicycle Therapeutics(BCYC.US), With a Forecast Between $32 to $55
Navigating 11 Analyst Ratings For Bicycle Therapeutics
Oppenheimer Remains a Buy on Bicycle Therapeutics (BCYC)
Optimistic Buy Rating for Bicycle Therapeutics Amid Promising Imaging Data and Strategic Market Positioning
Oppenheimer Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $48
Oppenheimer Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $48
Jefferies Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $56
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC) and Radnet (RDNT)